Celgene Accused Of Infringing Cancer Treatment Patent

Law360, New York (October 3, 2013, 5:48 PM EDT) -- Andrulis Pharmaceuticals Corp. accused rival drugmaker Celgene Corp. of inducing the infringement of a bone marrow cancer treatment by encouraging physicians to prescribe a drug cocktail covered by an Andrulis patent, according to a suit filed Wednesday in Delaware federal court.

The complaint alleged that Celgene has promoted the use of a combination of three of its drugs that infringes a patent held by Andrulis for treating multiple myeloma using the sedative thalidomide by itself or in concert with other anti-cancer agents.

"Celgene has taken affirmative...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.